Sparsentan is not registered and thus, is unavailable to the public. Or other companies to trial...
The first question I had upon reading this announcement was...
In order to generate these in-vitro data, is Dimerix now working in collaboration with Travere?
It doesn’t state it anywhere in the announcement.
I can’t envisage another way of gaining access to the drug...
If there is a collaboration, then watch out...
Hardly a meaningless announcement.
Ann: DMX-200 Competitive Position Further Enhanced, page-27
-
- There are more pages in this discussion • 40 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
43.5¢ |
Change
-0.015(3.33%) |
Mkt cap ! $239.5M | |||
| Open | High | Low | Value | Volume |
| 43.5¢ | 43.8¢ | 42.0¢ | $988.7K | 2.301M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 43.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 43.5¢ | 17061 | 1 |
View Market Depth
| Last trade - 16.10pm 04/09/2024 (20 minute delay) ? |
| DXB (ASX) Chart |